keyword
MENU ▼
Read by QxMD icon Read
search

lung cancer bone metastases

keyword
https://www.readbyqxmd.com/read/29159028/risk-factors-for-bone-metastasis-from-renal-cell-cancer
#1
Xuan-Yin Chen, Min Lan, Yang Zhou, Wen-Zhao Chen, Dong Hu, Jia-Ming Liu, Shan-Hu Huang, Zhi-Li Liu, Zhi-Hong Zhang
Objective: The prognosis for renal cell carcinoma (RCC) is related to a high rate of metastasis, including 30% of bone metastasis. In this study, we investigate the correlation between diverse clinical factors and bone metastases secondary from renal cell cancer (RCC), and to identify potential risk factors for bone metastasis in newly diagnosed patients and those who have already received treatment. Methods: The clinical data of 372 patients with RCC were reviewed from January 2000 to August 2016...
November 2017: Journal of Bone Oncology
https://www.readbyqxmd.com/read/29156903/gender-differences-in-pain-and-patient-reported-outcomes-a-secondary-analysis-of-the-ncic-ctg-sc-23-randomized-trial
#2
Selina Chow, Keyue Ding, Bo Angela Wan, Michael Brundage, Ralph M Meyer, Abdenour Nabid, Pierre Chabot, Genevievev Coulombe, Shahida Ahmed, Joda Kuk, A Rashid Dar, Aamer Mahmud, Alysa Fairchild, Carolyn F Wilson, Jackson S Y Wu, Kristopher Dennis, Carlo DeAngelis, Rebecca K S Wong, Liting Zhu, Edward Chow
BACKGROUND: Gender differences may contribute to variations in disease presentations and health outcomes. To explore the gender difference in pain and patient reported outcomes in cancer patients with bone metastases undergoing palliative radiotherapy on the National Cancer Institute of Canada (NCIC) SC.23 randomized trial. METHODS: Patients completed the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life (QOL) bone metastases module (QLQ-BM22) and EORTC QOL Core-15-Palliative (QLQ-C15-PAL) before treatment and at days 10 and 42 after a single 8 Gy radiation treatment...
August 29, 2017: Annals of Palliative Medicine
https://www.readbyqxmd.com/read/29156749/high-uric-acid-ua-downregulates-bone-alkaline-phosphatase-balp-expression-through-inhibition-of-its-promoter-activity
#3
Zhi-Qi Wu, Xiao-Ting Chen, Yan-Yan Xu, Ming-Jie Tian, Hai-Yan Chen, Guo-Ping Zhou, Hua-Guo Xu
Bone metastases often occur in prostate cancers, lung cancers and breast cancers. Bone alkaline phosphatase (BALP) is one of the most commonly used serological markers for clinical evaluation of bone metabolism. Here, we reported that high concentrations of uric acid (UA) caused decrease of BALP levels and revealed that the effect of high concentrations of UA on the BALP expression was through inhibition of its promoter activity. Our results suggested physicians to think about serum UA status of patients with advanced cancer to avoid misdiagnosis when BALP was used to diagnose or assess the extent of bone metastases...
October 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29151522/a-case-of-large-cell-neuroendocrine-carcinoma-harboring-an-alk-rearrangement-with-response-to-alectinib
#4
Nobuyoshi Hayashi, Akihisa Fujita, Toyohiro Saikai, Hirotugu Takabatake, Mie Sotoshiro, Kyuutarou Sekine, Akihiko Kawana
Anaplastic lymphoma kinase (ALK) rearrangement is most commonly observed in lung adenocarcinoma in a subset of lung cancer. Large-cell neuroendocrine carcinoma (LCNEC) harboring an ALK rearrangement is very rare. Based on the findings from a transbronchial lung biopsy, a 75-year-old non-smoking woman was diagnosed with LCNEC with multiple liver and bone metastases. After seven cycles of cytotoxic chemotherapy, her genotype testing demonstrated ALK rearrangement. Subsequently, she was administered alectinib and exhibited a partial response...
November 20, 2017: Internal Medicine
https://www.readbyqxmd.com/read/29135778/accuracy-of-medicare-claim-based-algorithm-to-detect-breast-prostate-or-lung-cancer-bone-metastases
#5
Nalini Sathiakumar, Elizabeth Delzell, Huifeng Yun, Rene Jooste, Kelly Godby, Carla Falkson, Mellissa Yong, Meredith L Kilgore
BACKGROUND: We had previously developed an algorithm for Medicare claims data to detect bone metastases associated with breast, prostate, or lung cancer. This study was conducted to examine whether this algorithm accurately documents bone metastases on the basis of diagnosis codes in Medicare claims data. METHODS: We obtained data from Medicare claims and electronic medical records of patients 65 years or older with a breast, prostate, or lung cancer diagnosis at a teaching hospital and/or affiliated clinics during 2005 or 2006...
December 2017: Medical Care
https://www.readbyqxmd.com/read/29120653/-thyroid-carcinomas-the-present-view-on-diagnostics-and-therapy
#6
Petr Vlček, Dana Nováková, Rami Katra
Thyroid carcinoma (TC) represents 1-2 % of all human tumors, and is the seventh most common tumor. Women are in large majority among new patients. For women, this is the fifth most common tumor. In the Czech Republic, 1 143 new cases of TC were diagnosed in 2015. It is the tumor with the highest increase in incidence. Among newly diagnosed tumors, most of those are differentiated thyroid gland carcinomas (DTCs) originating from follicular thyroid cells. These tumors are follicular and papillary carcinomas and Hurthle carcinoma, accounting for 95 % of new cases...
2017: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/29118670/an-overview-of-the-role-of-platelets-in-angiogenesis-apoptosis-and-autophagy-in-chronic-myeloid-leukaemia
#7
REVIEW
Lisa Repsold, Roger Pool, Mohammed Karodia, Gregory Tintinger, Annie Margaretha Joubert
Amongst males, leukaemia is the most common cause of cancer-related death in individuals younger than 40 years of age whereas in female children and adolescents, leukaemia is the most common cause of cancer-related death. Chronic myeloid leukaemia (CML) is a chronic leukaemia of the haematopoietic stem cells affecting mostly adults. The disease results from a translocation of the Philadelphia chromosome in stem cells of the bone marrow. CML patients usually present with mild to moderate anaemia and with decreased, normal, or increased platelet counts...
2017: Cancer Cell International
https://www.readbyqxmd.com/read/29117898/the-contribution-of-immune-infiltrates-and-the-local-microenvironment-in-the-pathogenesis-of-osteosarcoma
#8
Marie-Françoise Heymann, Frédéric Lézot, Dominique Heymann
Osteosarcoma is a rare primary bone cancer characterized by cancer cells producing calcified osteoid extracellular matrix and inducing lung metastases with a high frequency. The local microenvironment defined several tumor niches controlling the tumor growth and cell extravasation. The immune infiltrate composes one of these niches. The immune environment of osteosarcoma is mainly composed by T-lymphocytes and macrophages but also contains other subpopulations including B-lymphocytes and mast cells. Osteosarcoma cells control the recruitment and differentiation of immune infiltrating cells and establish a local immune tolerant environment favorable to the tumor growth, drug resistance and the occurrence of metastases...
November 2, 2017: Cellular Immunology
https://www.readbyqxmd.com/read/29108364/the-impact-of-post-radioiodine-therapy-spect-ct-on-early-risk-stratification-in-differentiated-thyroid-cancer-a-bi-institutional-study
#9
Szabina Szujo, Livia Sira, Laszlo Bajnok, Beata Bodis, Ferenc Gyory, Orsolya Nemes, Karoly Rucz, Peter Kenyeres, Zsuzsanna Valkusz, Krisztian Sepp, Erzsebet Schmidt, Zsuszanna Szabo, Sarolta Szekeres, Katalin Zambo, Sandor Barna, Endre V Nagy, Emese Mezosi
Objective: SPECT/CT has numerous advantages over planar and traditional SPECT images. The aim of this study was to evaluate the role of post-radioiodine therapy SPECT/CT of patients with differentiated thyroid cancer (DTC) in early risk classification and in prediction of late prognosis. Patients and methods: 323 consecutive patients were investigated after their first radioiodine treatment (1100-3700 MBq). Both whole body scan and SPECT/CT images of the head, neck, chest and abdomen regions were taken 4-6 days after radioiodine therapy...
October 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/29108326/serum-dickkopf-1-as-a-clinical-and-prognostic-factor-in-non-small-cell-lung-cancer-patients-with-bone-metastases
#10
Rong Qiao, Runbo Zhong, Qing Chang, Jiajun Teng, Jun Pei, Baohui Han, Tianqing Chu
Background: The study was designed to evaluate the association between serum dickkopf-1 (DKK1) and non-small cell lung cancer (NSCLC) bone metastases. Materials and Methods: Serum DKK1 levels were quantified in 470 NSCLC patients, 140 with osseous metastases, 178 with extraosseous metastases, and 152 with early stage in complete remission. The Receiver Operating Characteristic (ROC) curve enabled us to identify a threshold value to distinguish patients with bone metastases...
October 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/29105797/-99m-tc-mip-1404-spect-ct-for-the-detection-of-psma-positive-lesions-in-225-patients-with-biochemical-recurrence-of-prostate-cancer
#11
Christian Schmidkonz, Claudia Hollweg, Michael Beck, Julia Reinfelder, Theresa I Goetz, James C Sanders, Daniela Schmidt, Olaf Prante, Tobias Bäuerle, Alexander Cavallaro, Michael Uder, Bernd Wullich, Peter Goebell, Torsten Kuwert, Philipp Ritt
BACKGROUND: (99m) Tc-MIP-1404 (Progenics Pharmaceuticals, Inc., New York, NY) is a novel, SPECT-compatible (99m) Tc-labeled PSMA inhibitor for the detection of prostate cancer. We present results of its clinical use in a cohort of 225 men with histologically confirmed prostate cancer referred for workup of biochemical relapse. METHODS: From April 2013 to April 2017, (99m) Tc-MIP1404-scintigraphy was performed in 225 patients for workup of PSA biochemical relapse of prostate cancer...
November 6, 2017: Prostate
https://www.readbyqxmd.com/read/29102858/weekly-cabazitaxel-plus-prednisone-is-effective-and-less-toxic-for-unfit-metastatic-castration-resistant-prostate-cancer-phase-ii-spanish-oncology-genitourinary-group-sogug-trial
#12
Miguel Ángel Climent, Begoña Pérez-Valderrama, Begoña Mellado, Eva María Fernández Parra, Ovidio Fernández Calvo, María Ochoa de Olza, Laura Muinelo Romay, Urbano Anido, Montserrat Domenech, Susana Hernando Polo, José Ángel Arranz Arija, Cristina Caballero, María José Juan Fita, Daniel Castellano
AIM: Cabazitaxel (CBZ), a novel tubulin-binding taxane, improves overall survival in metastatic castration-resistant prostate cancer (mCRPC) that progresses during or after docetaxel treatment. We have designed a phase II study to evaluate the efficacy and safety of CBZ as a weekly schedule for 'unfit' mCRPC patients after docetaxel failure. METHODS: In this single arm phase II study. CBZ was weekly administered in 1-hour infusion on days 1, 8, 15 and 22, every 5 weeks at 10 mg/m(2) to eligible 'unfit' patients; oral prednisone (5 mg) was administered twice a day...
November 2, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29066702/-two-cases-in-which-eribulin-mesylate-was-effective-for-taxane-resistant-advanced-breast-cancer
#13
Keita Adachi, Shuhei Suzuki, Hitomi Kubota, Yukiko Hara, Asako Fujiwara, Eiko Waga, Tomohiro Hirano, Katsuhisa Enomoto, Kenichi Sakurai, Makoto Makishima, Tsugumichi Koshinaga
We experienced 2 cases in which eribulin mesylate was effective for taxane-resistant advanced breast cancer. Case 1: A 65- year-old woman was diagnosed with advanced breast cancer(T4cN2aM0, stage III B)and treated with chemotherapy(nabpaclitaxel). Bone metastasis was observed; then, she sequentially received epirubicin and cyclophosphamide, nab-paclitaxel, and bevacizumab and paclitaxel. However, lung metastases appeared, and we changed the regimen to eribulin mesylate. We administered 11 courses of eribulin mesylate before bone marrow metastasis appeared...
October 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29066121/patterns-of-intraosseous-recurrence-after-stereotactic-body-radiation-therapy-for-coxal-bone-metastasis
#14
Kei Ito, Takuya Shimizuguchi, Keiji Nihei, Tomohisa Furuya, Hiroaki Ogawa, Hiroshi Tanaka, Keisuke Sasai, Katsuyuki Karasawa
PURPOSE: To analyze the detailed pattern of intraosseous failure after stereotactic body radiation therapy (SBRT) for coxal bone metastasis. METHODS AND MATERIALS: Patients treated with SBRT to coxal bone metastasis were identified by retrospective chart review. The SBRT doses were 30 Gy or 35 Gy in 5 fractions. A margin of 5 to 10 mm was added to the gross tumor volume to create the clinical target volume. We evaluated the presence or absence of intraosseous recurrence using magnetic resonance imaging...
September 5, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29061956/oxycodone-resistance-due-to-rifampin-use-in-an-osteosarcoma-patient-with-tuberculosis
#15
Akio Sakamoto, Manato Yamashita, Yuta Hori, Takeshi Okamoto, Atsushi Shimizu, Shuichi Matsuda
BACKGROUND Oxycodone is a semisynthetic opioid receptor agonist, and is frequently used for pain control in patients with cancer. Most oxycodone is metabolized by N-demethylation to noroxycodone by CYP3A. Rifampin is a strong inducer of several drug-metabolizing enzymes, including CYP3A. Hence, rifampin-induced CYP3A activity may decrease the effect of oxycodone. CASE REPORT Osteosarcoma is a highly aggressive primary bone tumor of childhood and adolescence. Here, we report a 30-year-old male with osteosarcoma of the femur with lung metastases in the upper lobe...
October 24, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/29048237/lenvatinib-for-the-treatment-of-radio-iodine-refractory-thyroid-cancer-in-real-life-practice
#16
Amandine Berdelou, Isabelle Borget, Yann Godbert, Thierry Nguyen, Marie-Eve Garcia, Cecile N Chougnet, Aurélie Ferru, Camille Buffet, Olivier Chabre, Olivier Huillard, Sophie Leboulleux, Martin Schlumberger
BACKGROUND: In the SELECT phase III trial in advanced radio-iodine refractory differentiated thyroid cancer (rDTC), lenvatinib improved median progression free survival (PFS) over placebo by almost 15 months and induces an objective response rate of 64.8%, but adverse events occurred in almost all patients. The present study evaluates the efficacy and toxicity of lenvatinib treatment in real-life practice. METHODS: Clinical charts of 88 consecutive patients treated with lenvatinib from July 2015 to June 2016 in 27 French centers were retrospectively reviewed...
October 19, 2017: Thyroid: Official Journal of the American Thyroid Association
https://www.readbyqxmd.com/read/29046247/optimal-usage-of-radium-223-in-metastatic-castration-resistant-prostate-cancer
#17
REVIEW
Tai-Lung Cha, Tony Tong-Lin Wu, Nicholas John Vogelzang, Chao-Yuan Huang, Shu-Pin Huang, Chia-Chi Lin, Yen-Chuan Ou, See-Tong Pang, Daniel Heung-Yuan Shen, Wen-Jeng Wu, Wayne Yen-Hwa Chang
Radium-223 is a first-in-class α-emitting radiopharmaceutical that targets bone metastases associated with metastatic castration-resistant prostate cancer (mCRPC). In the pivotal phase III trial ALSYMPCA, radium-223 significantly increased overall survival (OS), compared with placebo (median 14.9 vs 11.3 months; hazard ratio 0.70; 95% CI 0.58-0.83; p < 0.001), in patients with mCRPC and symptomatic bone metastases-with a comparable safety profile. To optimize treatment outcomes, selection of appropriate patients is important...
November 2017: Journal of the Formosan Medical Association, Taiwan Yi Zhi
https://www.readbyqxmd.com/read/29026519/squamous-cell-carcinoma-arising-in-familial-gingival-fibromatosis-a-rare-case-report
#18
Dilasma Ghartimagar, Ujjwal Koirala, Arnab Ghosh, Manish Kiran Shrestha, Sushma Thapa, Raghavan Narasimhan, O P Talwar
Familial gingival fibromatosis is a rare hereditary condition due to chromosomal abnormality which can occur as an isolated disease or as part of a syndrome and has an incidence of 1:350 000. This condition leads to esthetic, functional, psychological and masticatory disturbance of the oral cavity. Here, we present a case of 21-year-old female with severe enlargement of gums in maxilla and mandible. Deciduous teeth were erupted at normal age but the permanent teeth in the oral cavity were not erupted. Her grandmother, father and younger sister were also affected with the same condition...
October 2017: Journal of Surgical Case Reports
https://www.readbyqxmd.com/read/29020102/dusp3-deletion-in-mice-promotes-experimental-lung-tumour-metastasis-in-a-macrophage-dependent-manner
#19
Maud Vandereyken, Sophie Jacques, Eva Van Overmeire, Mathieu Amand, Natacha Rocks, Céline Delierneux, Pratibha Singh, Maneesh Singh, Camille Ghuysen, Caroline Wathieu, Tinatin Zurashvili, Nor Eddine Sounni, Michel Moutschen, Christine Gilles, Cécile Oury, Didier Cataldo, Jo A Van Ginderachter, Souad Rahmouni
Vaccinia-H1 Related (VHR) dual-specificity phosphatase, or DUSP3, plays an important role in cell cycle regulation and its expression is altered in several human cancers. In mouse model, DUSP3 deletion prevents neo-angiogenesis and b-FGF-induced microvessel outgrowth. Considering the importance of angiogenesis in metastasis formation, our study aimed to investigate the role of DUSP3 in tumour cell dissemination. Using a Lewis Lung carcinoma (LLC) experimental metastasis model, we observed that DUSP3-/- mice developed larger lung metastases than littermate controls...
2017: PloS One
https://www.readbyqxmd.com/read/28988825/pgc-1%C3%AE-promotes-breast-cancer-metastasis-and-confers-bioenergetic-flexibility-against-metabolic-drugs
#20
Sylvia Andrzejewski, Eva Klimcakova, Radia M Johnson, Sébastien Tabariès, Matthew G Annis, Shawn McGuirk, Jason J Northey, Valérie Chénard, Urshila Sriram, David J Papadopoli, Peter M Siegel, Julie St-Pierre
Metabolic adaptations play a key role in fueling tumor growth. However, less is known regarding the metabolic changes that promote cancer progression to metastatic disease. Herein, we reveal that breast cancer cells that preferentially metastasize to the lung or bone display relatively high expression of PGC-1α compared with those that metastasize to the liver. PGC-1α promotes breast cancer cell migration and invasion in vitro and augments lung metastasis in vivo. Pro-metastatic capabilities of PGC-1α are linked to enhanced global bioenergetic capacity, facilitating the ability to cope with bioenergetic disruptors like biguanides...
November 7, 2017: Cell Metabolism
keyword
keyword
78717
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"